reports
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK21.00) - April traffic statistics p...
The April traffic statistics are due at 08:00 CET on 7 May. We expect Norwegian Air’s figures to be affected by the early timing of Easter and ramp up of capacity ahead of the summer season, forecasting a lower yield and load YOY. We reiterate our BUY and NOK21 target price.
Q1 update: Novonesis delivers 4% organic sales growth in line with exp...
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35%. COPENHAGEN, Denmark – May 3, 2024. In the first three months of the 2024 financial year, Novonesis delivers 4% organic sales growth against a strong comparator. The organic sales growth in the first quarter is driven by both Food & Health Biosolution...
Trading statement Q1 2024
Trading statement Q1 2024 Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4% with growth in both Food & Health and Planetary Health. We are off to a good start in line with expectations and very well on track to deliver 5-7% organic sales growth for the full year with an adjusted EBITDA margin of around 35%. It’s highly comforting to see our new organization’s focus on both short and long-term deliverables and developments.” Pro forma sales perfo...
Resolutions from the annual shareholders’ meeting 2024
Resolutions from the annual shareholders’ meeting 2024 Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.• Approval of the Remuneration Report fo...
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK21.00) - Weak Q1 due to higher cost...
Norwegian Air Shuttle traded down c7% on Wednesday on weaker than expected Q1 results hit by higher costs, which made the market question the reiterated 2024 CASK guidance. We reiterate our BUY but have lowered our target price to NOK21 (23) on negative estimate revisions, reflecting slightly revised cost assumptions.
- ABGSC Shipping & Transport Research
- Ali Shemmari
- Petter Nystrøm
DNB Bank ASA: 1 director
A director at DNB Bank ASA bought 6,000 shares at 205.710NOK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Invitation to the annual shareholders’ meeting
Invitation to the annual shareholders’ meeting The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and the Board of Directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 - December 31) of 2023. This equals a pay-out ratio of 53.2% of Novonesis’ adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a ...
Share-based legacy RSU program granted
Share-based legacy RSU program granted Share-based legacy RSU program granted Novonesis’ Board of Directors has following the merger with Chr. Hansen Holding A/S (“Chr. Hansen”) today approved the continuation in 2024 of a legacy Chr. Hansen annual short-term incentive program comprising of up to 125,000 restricted share units (RSUs) for around 130 legacy Chr. Hansen key employees below the Executive Management level. Receipt of the RSUs is subject to specified KPIs and criteria supporting performance and retention. The KPIs include personal targets and financial performance indi...
- Ole Martin Westgaard
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK20.00) - March traffic statistics
We consider this a slightly positive report for Norwegian Air Shuttle, including strong figures for Norwegian Air, slightly weak figures from Widerøe, and a cautious outlook for April. We expect 1–2% positive revisions to consensus 2024e EBITDA and believe a slightly positive share price reaction is warranted.
- Ole Martin Westgaard
2024 outlook and pro forma financials
2024 outlook and pro forma financials Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis, said: “Today we provide key pro forma numbers as well as the first outlook for our new company. On a pro forma basis, 2023 was a solid year for Novonesis, including a Chr. Hansen that on a stand-alone basis delivered well in range of its latest full year outlook. We expect a solid 2024 performance with overall organic sales growth of 5-7% including growth across all subareas, and a ...
Novonesis will host a conference call regarding 2024 outlook and 2023 ...
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET. To join the live webcast, please click . To register and receive access details for the conference call, please click . Attachment
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK20.00) - February traffic statistic...
We consider this a positive report for Norwegian Air Shuttle, with load and yield above expectations and positive outlook comments. We expect 1–2% positive revisions to consensus 2024e BITDA and believe a slight positive share price reaction is warranted.
Resolutions from the Extraordinary Shareholders’ Meeting 2024
Resolutions from the Extraordinary Shareholders’ Meeting 2024 Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders’ meeting was conducted. The following resolutions were made: Adoption of Novonesis A/S as secondary name and amendment of the Articles of Association in accordance herewithElection of Jesper Brandgaard as Vice Chair of the Board of DirectorsElection of Lise Kaae, Kevin Lane and Kim Stratton as members of the Board of Directors Following the extraordinary shareholders’ meeting, the Board of Directors consists of the following members: Cornelis ...
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK20.00) - February traffic statistic...
Norwegian Air Shuttle is due to report its February traffic statistics at 08:00 CET on 6 March. We are positive ahead of the report, expecting a continued strong yield trend YOY and a flat load factor MOM. We reiterate our BUY and NOK20 target price.
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK20.00) - Flying high
The Q4 results were strong, in line with the positive profit warning, and the 2024 EBIT guidance was significantly above consensus, in our view reflecting strong demand. We reiterate our BUY and have raised our target price to NOK20 (17), supported by positive estimate revisions.
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S An extraordinary shareholders’ meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark. Attachments
The Novozymes Report 2023
The Novozymes Report 2023 This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024. The new combined group is called Novonesis. As an annual report is required to cover the activities of a group during a financial year, this report only discloses Novozymes’ financial and non-financial performance in 2023. Non-financial elements concerning the combined group, Novonesis, are provided in separate and clearly labeled sections. Read more about Novonesis in the section The next step on our strategic journey. T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.